---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-034381"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:25:13.132394+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA requires confirmatory Phase 3 trial for apraglutide; Ironwood explores strategic alternatives

## Summary
- FDA feedback indicates a confirmatory Phase 3 trial is needed to seek approval of apraglutide for SBS-IF; company will work on design and regulatory path.
- Pharmacokinetic analysis found exposure and dose in STARS Phase 3 trial were lower than planned due to dose preparation and administration.
- Ironwood has engaged Goldman Sachs & Co. LLC to explore strategic alternatives to maximize stockholder value.
- Long-term extension data: 27 apraglutide-dosed patients achieved enteral autonomy (no parenteral support); STARS data remains part of NDA package.

## SEC filing metadata
- accession: 0001104659-25-034381
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465925034381/0001104659-25-034381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465925034381/tm2512215d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-034381
- JSON: https://secwatch.observer/filing/0001104659-25-034381.json
- Plain text: https://secwatch.observer/filing/0001104659-25-034381.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.